Cancer has long been the second-leading cause of death in the United States and represents the leading cause of death in midlife (age 40-60). While the prognosis for many cancers has vastly improved over the last thirty years, many cancers remain elusive due to the late-onset of symptoms, the specific...
Annual age-adjusted breast cancer incidence rates in the United States have been static for decades. More recently, the development of massively parallel, high throughput DNA sequencing has enabled the cataloging of somatic mutations in cancer. Mutations are non-random and occur within sequence motifs. These motifs provide us with evidence to...
The polypeptide hormone prolactin (PRL) is increasingly recognized as contributing to the development and progression of human breast cancer. This is supported by epidemiologic studies that found women with high levels of serum PRL are at an increased risk for developing breast cancer. Activation of the prolactin receptor (PRLR) by...
Tumor progression depends on both tumor-intrinsic processes and interactions with different cell types within tumor microenvironment. Identifying targets that have dual effects on both tumor cells and their interacting surrounding cells, such as tumor-infiltrating immune cells, represent a novel therapeutic approach to treat cancer patients
CD44 is a ubiquitously expressed...